Skip to main content

Disopyramide Side Effects

Medically reviewed by Last updated on Dec 18, 2023.

Applies to disopyramide: oral capsule, oral capsule extended release.


Oral route (Capsule; Capsule, Extended Release)

An increase in mortality has been reported in patients receiving encainide or flecainide after myocardial infarction for asymptomatic non life threatening ventricular arrhythmias. Considering the known proarrhythmic properties of disopyramide and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of disopyramide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.

Serious side effects of Disopyramide

Along with its needed effects, disopyramide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking disopyramide:

More common

Less common


Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking disopyramide:

Symptoms of overdose

Other side effects of Disopyramide

Some side effects of disopyramide may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to disopyramide: compounding powder, oral capsule, oral capsule extended release.


Gastrointestinal side effects including anticholinergic side effects have been the most common cause of gastrointestinal complaints. Dry mouth (40%), constipation (11%) and nausea, pain/bloating/gas (3% to 9%) have been reported. Anorexia, diarrhea, and vomiting have occurred. Two cases of paralytic ileus have been reported. A case of oral mucosal ulceration has been associated with the (unapproved) sublingual use of disopyramide.[Ref]


Cardiovascular side effects have included arrhythmias, conduction disturbances, hypotension, and heart failure. Like other class I antiarrhythmic agents, disopyramide can be proarrhythmic and decrease cardiac contractility. The risk of proarrhythmias may be increased in patients with left ventricular dysfunction. Various ventricular tachyarrhythmias accompanied by disopyramide-induced QT interval prolongation, including ventricular tachycardia or fibrillation and torsades de pointes, have been associated with usual therapeutic doses. Evidence of QRS segment or QT widening are indications to either reduce the dose or stop the drug. Conduction disturbances, including AV block, have occurred, and are more likely in patients with preexisting conduction disorders.[Ref]

Contributing factors towards the development of torsades de pointes included female gender, hypokalemia, underlying arrhythmias, mitral valve abnormalities, or congestive heart failure.

Hypotension, pulmonary edema, and frank cardiogenic shock have been associated with both the oral and intravenous administration of disopyramide. Most affected patients had underlying congestive heart failure.[Ref]

Nervous system

A patient developed a severe sensory-motor polyneuropathy after receiving disopyramide 500 mg daily for 4 years. Symptoms did not respond to corticosteroids, but did resolve a few months after withdrawal of disopyramide.[Ref]

Nervous system side effects including anticholinergic symptoms have been reported. Other nervous system side effects have been rare, and included nervousness, insomnia, depression, and peripheral paresthesia or neuropathy.[Ref]


Genitourinary side effects were related to anticholinergic properties of the drug. Urinary hesitancy (10% to 40%) has occurred. Urinary retention, frequency, and urgency has been reported in up to 9% of patients. Recommended management consisted of lowering the dose, discontinuing the drug, or if necessary, using a cholinergic drug to counteract this effect. Sexual impotence has been reported.[Ref]


Hepatic side effects including reversible, dose-independent intrahepatic cholestasis, hepatocellular damage, and nonspecific hepatic inflammatory changes have been reported in rare cases where venous congestion secondary to heart failure was reasonably excluded. Manifestations of liver dysfunction usually appeared during the first week of treatment (malaise, dark urine) and resolved promptly upon discontinuation of the drug. In one review, 20 cases were reported during a 14-year period.[Ref]


Endocrine side effect have included hypoglycemia due to stimulation of insulin secretion and rare cases of hypokalemia and dyslipidemia. Hypoglycemia can occur in nondiabetic patients at therapeutic plasma disopyramide levels.[Ref]

Elevated insulin levels have been measured during disopyramide-associated hypoglycemic episodes. Data have revealed that disopyramide blocks pancreatic ATP-sensitive potassium channels, enhancing insulin release. Other factors such as increased peripheral utilization of glucose or decreased glycogenolysis have not been fully evaluated.[Ref]


Immunologic side effects, such as the production of antinuclear antibodies and other immunologically-mediated changes associated with other class 1 antiarrhythmic agents, do not appear to occur during disopyramide therapy.[Ref]


Dermatologic reactions have been reported rarely, usually presenting as a rash or pruritus.[Ref]


Ocular side effects of blurred vision (3% to 9%) have been associated with the anticholinergic effects of disopyramide.[Ref]


General body symptoms of fatigue, muscle weakness, malaise, and aches/pains have been reported in 3% to 9% of patients administered disopyramide. Rarely, fever has occurred.[Ref]


Psychiatric side effects including reversible psychiatric symptoms of psychosis have been reported rarely.[Ref]


Hematologic adverse effects of thrombocytopenia, and reversible agranulocytosis have occurred rarely.[Ref]


Gynecomastia has been reported.[Ref]


Respiratory difficulty has been reported rarely.[Ref]


1. Ekelund LG, Nilsson E, Walldius G. Efficacy of and adverse effects of disopyramide. Eur J Clin pharmacol. 1986;29:673-7.

2. Ahmad S. Disopyramide-related paralytic ileus: case report. J Am Geriatr Soc. 1991;39:317-8.

3. Product Information. Norpace (disopyramide). Searle. 2001;PROD.

4. Witkowsky AK, Reddy R, Bardy GH. Oral mucosal ulceration from disopyramide. Ann Pharmacother. 1995;29:1299.

5. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin: an update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs. 1995;2:295-320.

6. Lo KS, Gantz KB, Stetson PL, et al. Disopyramide-induced ventricular tachycardia. Arch Intern Med. 1980;140:413-4.

7. Kinney EL, Field EH, Salmon MP, Zelis R. Cardiac arrhythmias associated with disopyramide. N Engl J Med. 1990;May:1146.

8. Podrid PJ, Schoeneberger A, Lown B. Congestive heart failure caused by oral disopyramide. N Engl J Med. 1980;302:614-7.

9. Chia BL. Disopyramide induced atypical ventricular tachycardia. Aust N Z J Med. 1980;10:665-8.

10. Porterfield JG, Antman EM, Lown B. Respiratory difficulty after use of disopyramide. N Engl J Med. 1980;303:584.

11. Sinatra ST, Landry AB, Galle JS, Amato J. Cariogenic shock associated with disopyramide phosphate. JAMA. 1980;243:1132.

12. Tonkin AM, Joel SE, Reynolds JL. Unusual hepatocellular and cardiovascular complications of disopyramide. Chest. 1980;77:125.

13. Tzivoni D, Keren A, Stern S, Gottlieb S. Disopyramide-induced Torsade de pointes. Arch Intern Med. 1981;141:946-7.

14. Bauman DJ. Myocardial depression with disopyramide. Ann Intern Med. 1981;94:411-2.

15. Timins BI, Gutman JA, Haft JI. Disopyramide-induced heart block. Chest. 1981;79:477-9.

16. Desai JM, Scheinman MM, Hirschfeld D, et al. Cardiovascular collapse associated with disopyramide therapy. Chest. 1981;79:545-51.

17. Schweitzer P, Mark H. Torsade de pointes caused by disopyramide and hypokalemia. Mt Sinai J Med. 1982;49:110-4.

18. Timins BI. Disopyramide and bundle-branch block. Ann Intern Med. 1982;96:684.

19. Riccioni N, Castiglioni M, Bartolomei C. Disopyramide-induced QT prolongation and ventricular tachyarrhythmias. Am Heart J. 1983;105:870-1.

20. Simpson RJ, Foster JR, Benge C, et al. Safety of multiple bolus loading of intravenous disopyramide. Am Heart J. 1983;106:505-8.

21. Bauman JL, Gallasategui J, Strasberg B, et al. Long-term therapy with disopyramide phosphate: side effects and effectiveness. Am Heart J. 1986;111:654-60.

22. Brogden RN, Todd PA. Disopyramide: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias. Drugs. 1987;34:151-87.

23. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-7.

24. Masuhara K, Ohno T, Hamaguchi K, Katoh K, Kashiwada K, Takahashi S, Tanaka Y, Someya K, Ogata H. Relationship between the therapeutic effects or side-effects and the serum disopyramide or mono-n-dealkylated disopyramide concentration after repeated oral administration of disopyramide to arrhythmic patients. Int J Clin Pharmacol Res. 1995;15:103-13.

25. Teichman SL, Fisher JD, Matos JA, Kim SG. Disopyramide-pyridostigmine: report of a beneficial drug interaction. J Cardiovasc Pharmacol. 1985;7:108-13.

26. Teichman SL, Ferrick A, Kim SG, et al. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect. J AM Coll Cardiol. 1987;10:633-41.

27. Briani C, Zara G, Negrin P. Disopyramide-induced neuropathy. Neurology. 2002;58:663.

28. Ahmad S. Disopyramide and impotence. South Med J. 1980;73:958.

29. Danziger LH, Horn JR. Disopyramide-induced urinary retention. Arch Intern Med. 1983;143:1683-6.

30. Craxi A, Gatto G, Maringhini A, et al. Disopyramide and cholestasis. Ann Intern Med. 1980;93:150-1.

31. Doody PT. Disopyramide hepatotoxicity and disseminated intravascular coagulation. South Med J. 1982;75:496-8.

32. Bakris GL, Cross PD, Hammarsten JE. Disopyramide-associated liver dysfunction. Mayo Clin proc. 1983;58:265-7.

33. Antonelli D, Koltun B, Barzilay J. Acute hepatotoxic effect of disopyramide. Chest. 1984;86:274.

34. Goldberg IJ, Brown LK, Rayfield EJ. Disopyramide (norpace)-induced hypoglycemia. Am J Med. 1980;69:463-6.

35. Quevedo SF, Krauss DS, Chazan JA, et al. Fasting hypoglycemia secondary to disopyramide therapy. JAMA. 1981;245:2424.

36. Semel JD, Wortham E, Karl DM. Fasting hypoglycemia associated with disopyramide. Am Heart J. 1983;106:1160-1.

37. Nappi JM, Dhanani S, Lovejoy JR, VanderArk C. Severe hypoglycemia associated with disopyramide. West J Med. 1983;138:95-7.

38. Rubin M, Zakheim B, Pitchumoni C. Disopyramide-induced profound hypoglycemia. N Y State J Med. 1983;July,Aug,S:1057-8.

39. Croxson MS, Shaw DW, Henley PG, Gabriel HDLL. Disopyramide-induced hypoglycaemia and increased serum insulin. N Z Med J. 1987;July:407-8.

40. Hayashi S, Horie M, Tsuura Y, Ishida H, Okada Y, Seino Y, Sasayama S. Disopyramide blocks pancreatic ATP-sensitive K+ channels and enhances insulin release. Am J Physiol. 1993;265:c337-42.

41. Wanner WR, Irvin WS. Disopyramide and antinuclear antibodies. Am Heart J. 1981;101:687-9.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.